FDA grants Merck's anti-PD-1 melanoma drug priority review
This article was originally published in Scrip
Executive Summary
Merck revealed on 6 May its biologics license application for the firm's investigational anti-PD-1 antibody MK-3475 was granted a priority review by the FDA, which set the Prescription Drug User Fee Act action date at 28 October.